Numerous studies investigating GSTP1, RARB and RASSF1 DNA promoter methylation have reported that hypermethylation in prostate tumour tissue may represent a biomarker of early cancer diagnosis, in accordance with our results [29, 30]. Here, RASSF1 is linked to cancer.